BTIG Maintains Sell on Integra Lifesciences, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Sell rating on Integra Lifesciences and lowers the price target from $22 to $20.
August 28, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BTIG analyst Ryan Zimmerman maintains a Sell rating on Integra Lifesciences and lowers the price target from $22 to $20, indicating a bearish outlook.
The maintenance of a Sell rating and the reduction of the price target from $22 to $20 by BTIG suggests a negative outlook on Integra Lifesciences' stock. This is likely to put downward pressure on the stock price in the short term as investors react to the bearish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100